中材國際(600970.SH):中標約28.17億元埃及國防部卡夫拉謝赫住房建設項目
格隆匯6月7日丨中材國際(600970.SH)公吿,近日,公司全資子公司成都建築材料工業設計研究院有限公司的埃及分公司(“成都院埃及分公司”)收到阿拉伯埃及共和國國防部工程局大項目部出具的《中標通知書》,確認成都院埃及分公司中標埃及國防部卡夫拉謝赫住房建設工程總承包項目,項目中標總價摺合人民幣約為28.17億元。
項目內容為建設109棟12層住宅,總建築面積約112萬平方米,這包含通用工程、給排水工程、電氣工程等工作。項目工期為無障礙場地移交後22個月完工。
如果該項目簽訂正式合同並順利實施,將為公司境外多元化項目的開拓提供更多的經驗,並將對公司未來的經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.